Scientists in the UK have developed a blood test which detects the recurrence of lung cancer in patients up to a year before the disease can be detected by CT scans and X-rays.
The groundbreaking TRACERx study, funded by Cancer Research UK, identified the cause of relapse of the disease and how it spreads, in a discovery that could lead to earlier treatment for patients.
By analysing tumours from 100 lung cancer patients, researchers at medical research centre Francis Crick Institute found that those containing a higher proportion of "unstable chromosomes" - those which cause genetic chaos and allow the tumour to evolve - were four times more likely to encounter a relapse or die within two years.
Genetically diverse tumours are harder to treat as they are more likely to spread and become drug-resistant.
In a study using 96 of those 100 patients, scientists screened their blood for circulating tumour DNA - bits of DNA that had "broken off" from a tumour - in order to uncover defects present in the patient's cancer.